DIFFMASTER OCTAVIA AUTOMATIC HEMATOLOGY ANALYZER

by CELLAVISION AB  · Based in Sweden →Pioneering digital hematology microscopy solutions for automated cell analysis.
Hematology Laboratory Medicine Pathology

Regulatory Status Disclosed

Overview

The DIFFMASTER OCTAVIA AUTOMATIC HEMATOLOGY ANALYZER, developed by CellaVision AB, was an early automated cell-locating device designed for in-vitro diagnostic use in clinical laboratories. Launched in early 2001, it aimed to automate and simplify the process of performing differential counts of white blood cells (WBC) and characterizing red blood cell (RBC) morphology, tasks traditionally conducted through manual microscopy. The system utilized a proprietary software system (Cytologica) combined with a sophisticated hardware platform to automatically locate and capture high-quality digital images of blood cells on peripheral blood specimens. It leveraged artificial neural networks for the pre-classification of leukocytes, presenting these images for review and verification by a skilled operator. While innovative for its time, the DiffMaster Octavia was CellaVision’s first product and was later discontinued, with approximately 80 systems sold before being succeeded by more automated and higher-throughput models like the CellaVision DM96.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated cell locating on blood smears
  • Differential count of white blood cells (WBC)
  • Characterization of red blood cell (RBC) morphology
  • Digital imaging of blood cells
  • Software-based pre-classification using artificial neural networks
  • Operator review and verification of cell classification
  • Aimed at improving efficiency and diagnostic quality in hematology labs
  • High image quality and user-friendly interface

Use Cases

  • Routine analysis of peripheral blood samples in hematology laboratories
  • Automated differential count of white blood cells
  • Automated characterization of red blood cell morphology
  • Preclassification of leukocytes in patients with hematological diseases
  • Replacing or assisting manual microscopy for blood cell analysis

What Physicians Need to Know

LIS/LIMS Integration
The system facilitates sharing patient information between departments for diagnosis and treatment, implying connectivity with laboratory information systems. It can be connected to an Ethernet for telehematologic diagnosis and consultation.
Supported Assay Types
Automated differential count of white blood cells (WBCs) and characterization of red blood cell (RBC) morphology. It preclassifies WBCs into 12 cell classes, including segmented neutrophils, band neutrophils, eosinophils, basophils, lymphocytes, monocytes, blast cells, promyelocytes, myelocytes, metamyelocytes, unidentified cells, erythroblasts, giant platelets, smudge cells, and artifacts. It also pre-characterizes red blood cells into 6 types based on shape, form, and color.
QC/QA Features
Demonstrates high reproducibility and accuracy in preclassification of leukocytes (overall accuracy 93.0%, clinical sensitivity 97.7%). Within-run imprecision was found to be high for both mature and blast cells.
Result Interpretation AI
Utilizes Artificial Neural Networks (ANNs) for automatic cell location, image processing, and preclassification of blood cells. It suggests a cell class for each cell to aid technologists.
Critical Value Alerts
Specific critical value alert functionality within the instrument is not explicitly detailed in the provided information. However, as a diagnostic tool, its results would contribute to data used by laboratory information systems (LIS) to trigger such alerts.
Instrument Interfaces
Comprises a motorized microscope (e.g., Olympus BX50WI), a 3-chip color CCD camera (e.g., Sony DXC-9100P), an automated motorized stage holder (eight-slide capacity), hardware for motor and light control, and a computer operating with Cytologica software. It can be connected to an Ethernet.
Reference Range Intelligence
Evaluates cells and provides preclassifications based on established morphological criteria. Clinical performance, including sensitivity and specificity, is assessed against reference methods.
Turnaround Time Impact
Significantly reduces analysis time compared to manual microscopy. The average analysis time was approximately 4.5 minutes per slide, which is shorter than the approximately 6.8 minutes per slide for manual methods. Preclassification time was about 2.3 minutes shorter than manual microscopy.
Physician Tip

The DiffMaster Octavia provides rapid and accurate preclassification of white and red blood cells, enhancing efficiency in hematology diagnostics. Physicians should note that while the system offers AI-assisted preclassification, a skilled technologist is still required to review and confirm or modify the suggested cell classifications, ensuring high-quality differential counts. This tool can lead to faster turnaround times for blood smear analysis, aiding in quicker diagnostic decisions, especially in conditions requiring urgent leukocyte classification, such as hematological diseases.

The DiffMaster Octavia is designed to integrate into laboratory workflows by enabling the sharing of patient information and facilitating telehematologic consultations via Ethernet connectivity. This implies compatibility with broader laboratory information systems (LIS/LIMS) for seamless data transfer and centralized review of results and images, which is crucial for efficient laboratory operations and patient management.

Details

Category Lab & Diagnostics, Pathology AI
Pricing Unknown
DeploymentOn-premise (physical analyzer)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The DiffMaster Octavia™ Automatic Hematology Analyzer received FDA 510(k) clearance (K003301) on March 15, 2001. It is classified as a Class II automated cell-locating device (21 CFR 864.5260, product code JOY) intended for in-vitro diagnostic use.

Integrations
EHR Not specified
Specialties Hematology, Laboratory Medicine, Pathology

What the Web Says

The CellaVision DIFFMASTER OCTAVIA AUTOMATIC HEMATOLOGY ANALYZER was an automated hematology analyzer cleared by the FDA in 2001. It utilized digital imaging and artificial intelligence to pre-classify white blood cells and characterize red blood cell morphology on peripheral blood smears, aiming to improve efficiency in clinical laboratories. However, the product has since been discontinued, with only about 80 systems sold before CellaVision developed the higher-throughput DM96. Reviews indicate that while it offered automation and improved efficiency for routine samples, it had limitations with abnormal samples and specific cell morphologies.

Overall: Mixed

Strengths

  • Automated morphological analysis of peripheral blood films.
  • Improved efficiency and reduced turnaround time for routine films.
  • Good correlation with manual differentiation for WBC analysis.
  • Ability to take screenshots and save cases for sharing and education.
  • Reduced labor costs and physical occupational health and safety hazards compared to conventional microscopy.

Limitations

  • Discontinued product.
  • Did not meet expected success, with low sales numbers.
  • Limitations with body fluids, especially those with low WBC counts, often failing analysis.
  • Difficulty in identifying certain RBC morphologies (e.g., HJ bodies) due to inability to focus up and down on the slide.
  • Sometimes selected poor areas of the slide for RBC morphology analysis.
  • Classification accuracy depended on the type of pathological changes in the blood sample, operating most effectively with non-pathological samples.
  • Steep learning curve for new staff and experienced morphologists had trouble trusting it.
  • Challenges with critical blood film abnormalities, including detection of platelet clumping and blast cells.

Based on reviews from: Medical AI Tools for Physicians, ResearchGate, Reddit, PubMed, American Journal of Clinical Pathology, J-Stage, FDA, Innolitics

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate DIFFMASTER OCTAVIA AUTOMATIC HEMATOLOGY ANALYZER

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

CellaVision
CellaVision, Lund, Sweden has obtained FDA clearance to introduce its DiffMaster(TM) Octavia, an in-vitro diagnostic device, on the U.S. market.
CellaVision announced on March 29, 2001, that its DiffMasteru2122 Octavia, an in-vitro diagnostic device, received FDA clearance for the U.S. market. This system automates the differential counting of white blood cells and assessment of red morphology, tasks traditionally performed by manual microscopy.
2001-03
Predicase
DIFFMASTER OCTAVIA AUTOMATIC HEMATOLOGY ANALYZER (K003301) - FDA 510(k) Clearance | Predicase
The FDA granted 510(k) clearance to the DIFFMASTER OCTAVIA AUTOMATIC HEMATOLOGY ANALYZER on March 15, 2001, classifying it as a Class II medical device. The product code for this device is JOY, indicating its function as an automated hematology differential cell counter.
2001-03
510k Monitor
K003301: DIFFMASTER OCTAVIA AUTOMATIC HEMATOLOGY ANALYZER - 510k Monitor
The FDA 510(k) clearance for the DIFFMASTER OCTAVIA AUTOMATIC HEMATOLOGY ANALYZER (K003301) by CellaVision AB was issued in 2001. This entry also notes that the device was last cleared on October 16, 2020, and June 27, 2025, and there are no recalls specifically linked to this clearance in FDA records.
2026-07
PubMed (Journal of Clinical Pathology)
Examination of peripheral blood films using automated microscopy; evaluation of Diffmaster Octavia and Cellavision DM96 - PubMed
A 2007 study evaluated the CellaVision Diffmaster Octavia and Cellavision DM96 for automated peripheral blood smear examination, finding overall preclassification accuracies of 87% and 92% respectively. Both systems showed good correlation with manual differentiation for WBC analysis, with the DM96 offering faster total analysis times.
2007-01
CellaVision
The history of CellaVision devices
The DiffMaster Octavia, launched in early 2001, was CellaVision's first product, featuring a modified microscope, an 8-slide stage, and software for pre-classifying white and red blood cells. Despite its innovation, only about 80 systems were sold before it was discontinued, leading to the development of the higher-throughput CellaVision DM96.
2001-01
Innolitics
AI/ML in Digital Pathology and the Software-as-an-IVD Paradigm: 2026 Snapshot - Innolitics
A 2026 snapshot on AI/ML in digital pathology mentions the CellaVision DiffMaster Octavia (2001) as an early example of hematology analyzers quietly using machine learning. Hematology and body-fluid analyzers dominate by volume in AI/ML authorizations, with CellaVision's automated white-blood-cell classifier iterating on the FDA since 2001.
2026-04
J-Stage (Japanese Journal of Medical Technology)
Future trends in AI (artificial intelligence) technology in clinical lab testing - J-Stage
A 2026 article on AI trends in clinical lab testing lists the DiffMaster Octavia Automatic Hematology Analyzer by CellaVision AB as an example of an AI-enabled medical device for red blood cell counting. The article discusses the increasing implementation of AI in diagnostic imaging and pathology, and regulatory trends across Japan, the US, and Europe.
2026-01
Oxford Academic (American Journal of Clinical Pathology)
critical analysis of CellaVision systems in the modern hematology laboratory | American Journal of Clinical Pathology | Oxford Academic
A 2025 critical analysis of CellaVision systems references a 2007 study on the Diffmaster Octavia and CellaVision DM96, highlighting the systems' ability to characterize common cellular morphology with high accuracy. The article emphasizes the need for continued research to support the transition of digital morphology systems into routine clinical practice.
2025-05

Videos

Product demos, reviews, and walkthroughs for DIFFMASTER OCTAVIA AUTOMATIC HEMATOLOGY ANALYZER.

View all on YouTube

Frequently Asked Questions

The DiffMaster Octavia utilizes artificial neural networks (ANNs) for the preclassification of white and red blood cells, automatically locating and presenting cell images for review. This acts as a decision support system, improving efficiency by pre-sorting cells and aiding technologists in performing differential counts, though final verification by a skilled operator is required.
The DiffMaster Octavia received FDA 510(k) clearance in March 2001 as an automated differential cell counter, classified as a Class II device. While it complies with general GMP regulations, specific modern data privacy standards like HIPAA for its AI components were not explicitly detailed at its initial clearance given the technology landscape at that time.
The DiffMaster Octavia, introduced in 2001, primarily uses ANNs for preclassification, requiring manual verification. Newer hematology analyzers often offer more advanced AI for comprehensive 5-part or even 7-part differentials, higher throughput, and reduced manual review rates, with some featuring integrated digital morphology and advanced flagging systems.
Specific current pricing for the older DiffMaster Octavia is not readily available, but hematology analyzers generally range from $5,000 to over $100,000, with older or refurbished models being less expensive. The total cost typically includes the analyzer, reagents, consumables, and service contracts, though explicit AI software licensing costs for this older model are not detailed.
The DiffMaster Octavia's preclassification accuracy can vary with pathological changes, performing most effectively on non-pathological samples. It requires uniform smear quality and a skilled operator to confirm or modify its suggested cell classifications, particularly for immature or atypical cells, which it may not accurately recognize.
As a device cleared in 2001, the original DiffMaster Octavia's data security features would align with the standards of that era. While CellaVision's current systems emphasize stricter IT security, the Octavia primarily functions as an image acquisition and preclassification tool, with patient data handling and privacy largely managed by the laboratory's overarching LIS and institutional policies.

Related Tools

Allergios®
Allergios®
Lab & Diagnostics
Allergios® is developing an in-vitro diagnostic system that directly visualizes allergic responses in blood serum to provide unambiguous allergy diagnoses, starting with food allergies.
PNOĒ
PNOĒ
Endocrinology & Metabolic AI
PNOĒ is a science-backed cardiometabolic analyzer that performs comprehensive breath-based assessments to measure 23 biomarkers, including VO₂ max, resting metabolic rate (RMR), fat burn efficiency, and biological age. It delivers a 360° snapshot of an individual's physiology by analyzing how oxygen flows through the lungs, heart, and cells. The insights generated are used to personalize nutrition, exercise, and longevity plans.
Folklore Clinical Variant Interpretation
Helena Bioinformatics
Lab & Diagnostics
Folklore is a clinical variant interpretation platform for genetic laboratories and researchers that brings genomic annotation, ACMG/AMP classification, phenotype and inheritance evidence, literature, and structured reporting into one traceable workflow.
Insitro
Insitro
Drug Discovery & Research
Insitro combines automated cellular experiments with population-scale genetics to build Physical AI systems that reveal causal drivers of human disease and deliver targeted therapeutics.
Freenome
Freenome
Clinical Decision Support & Reference
Freenome develops AI-powered, blood-based screening tests for early cancer detection using multiomics technology.
Mirvie
Mirvie
Clinical Decision Support & Reference
Mirvie is shaping the future of pregnancy health by providing women, expecting parents, and their doctors with an early detection window to intervene before unexpected pregnancy complications become a crisis.

See all Lab & Diagnostics tools →

More from CellaVision AB

Advanced RBC Application
CellaVision AB
Lab & Diagnostics
CellaVision Advanced RBC Application is an AI-powered software module that automates and standardizes the morphological examination of red blood cells, complementing peripheral blood smears for enhanced diagnostic efficiency in hematology labs.
CellaVision DC-1
CellaVision AB
Lab & Diagnostics
CellaVision DC-1 is an AI-powered digital cell morphology analyzer that automates and standardizes blood cell differentials in low-volume hematology laboratories, enhancing efficiency and diagnostic accuracy through digital imaging and pre-classification.
CELLAVISION DM1200 WITH THE BODY FLUID APPLICTION
CELLAVISION AB
Lab & Diagnostics
The CellaVision DM1200 with the Body Fluid Application is an FDA-cleared automated digital cell morphology system that uses AI and robotics to simplify and standardize blood and body fluid differentials in hematology labs.
CELLAVISION DM96 AUTOMATIC HEMATOLOGY ANALYZER
CELLAVISION AB
Lab & Diagnostics
The CellaVision DM96 Automatic Hematology Analyzer was an automated image analysis system that revolutionized hematology laboratories by providing digital solutions for differential counting of white blood cells and characterization of red blood cells, leveraging AI for pre-classification and enhancing workflow efficiency.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.